Women’s Health Patents: Recent Updates
- May is national Women’s Health Month, highlighting the importance of women's health issues.
- The femtech market is booming, exceeding $50 billion in 2023, with projections surpassing $100 billion by 2028.
- This increased focus is driving patent filings related to conditions like breast cancer, endometriosis, and infertility.
Explore the latest advancements in women’s health with a deep dive into recent patent trends. Breast cancer research continues to evolve, with developments in hormone receptor modulators and vaccine technologies marking significant progress within this primary_keyword. We also observe noteworthy strides in depression therapies, including psychedelic drugs and EEG biomarkers, all aimed at personalized treatment. Furthermore, uncover innovations in endometriosis, featuring non-surgical diagnostics and RNA therapies, alongside fertility advancements. This report from News Directory 3 details the cutting-edge patents in these crucial areas of women’s healthcare. Discover how the secondary_keyword,PCOS,is also seeing therapeutic innovation. What’s the future of women’s health?
Women’s Health: Innovations and Patent Trends
Updated May 29, 2025
May is national Women’s Health Month, highlighting the importance of women’s health issues. Despite comprising nearly half the global population, women often face disparities in healthcare. These include diagnosis, treatment, and overall health outcomes. Systemic inequalities and cultural biases contribute to these challenges.
However, the landscape is shifting. The femtech market is booming, exceeding $50 billion in 2023, with projections surpassing $100 billion by 2028. Venture capital funding for women’s health companies has also seen critically important growth.
This increased focus is driving patent filings related to conditions like breast cancer, endometriosis, and infertility. Here’s a look at recent U.S. patents and applications impacting women’s health.
Breast Cancer Innovations
Breast cancer is a leading cancer diagnosis for women.Recent patents are expanding on established treatment approaches.
Hormone receptor modulators remain a key area. Estrogen plays a significant role in hormone receptor-positive (HR+) breast cancers, making estrogen receptor function a prime target for drug development. In April 2025, the USPTO granted U.S. Patent No. 12,275,684 to Atossa Therapeutics, Inc., for oral formulations of (Z)-endoxifen, a Selective Estrogen Receptor Modulator (SERM). The company is studying its potential in breast cancer prevention and treatment.
The Cleveland Clinic Foundation has also seen progress with its patent application (Pub. No. 2024/0075115) for a vaccine containing human α-lactalbumin protein, present in certain breast cancers.
Depression Therapies
Women experience major depression at higher rates than men. Recent patents offer new therapeutic avenues.
Psychedelic drugs are gaining traction. Cybin Inc. recently secured three patents (U.S. Patent Nos. 12,251,371,12,240,813,and 12,291,499) for a psilocybin-derived drug (CYB003) targeting major depression. The FDA granted CYB003 Breakthrough Therapy Designation, expediting its development.
alto Neuroscience, Inc. received U.S. Patent no. 12,226,375 for using EEG biomarkers to guide treatment with agomelatine in patients unresponsive to customary antidepressants.
Endometriosis Advances
Endometriosis affects approximately 10% of women, causing pelvic pain and potential infertility. Diagnosis is challenging, and there is currently no cure. Recent patents focus on diagnostics and treatments using oligonucleotides.
Yale University received U.S. Patent No.12,077,8